文献速递前列腺癌

转移性激素敏感性前列腺癌中雄激素剥夺治疗强化的真实世界应用:一项系统综述

Real-world use of androgen-deprivation therapy intensification for metastatic hormone-sensitive prostate cancer: a systematic review.
PubMed 文献 · BJU Int · 2024-11-12

本系统综述检索截至2023年7月的真实世界数据研究,纳入29项研究,覆盖北美、欧洲和亚洲。结果显示各地域均以ADT单药治疗为主,ADT联合ARPI在美国和欧洲使用较多但亚洲较低,近期癌症中心/登记数据显示美国和欧洲ADT+ARPI使用超过40%。

要点

  • 多数研究为回顾性队列(26项),中位年龄≥70岁的研究有20项。
  • ADT单药治疗在各地区均占主导,ADT+ARPI和ADT+多西他赛在美国和欧洲使用较多,亚洲各联合方案使用均较低。
  • 近期癌症中心/登记电子病历数据显示美国和欧洲ADT+ARPI使用超过40%。

核心结论

  • 研究期间各地域ADT强化治疗呈上升趋势,但考虑到仍接受ADT单药治疗的患者比例很高,使用仍不理想。
  • 这些发现凸显需要干预措施以进一步优化当前mHSPC治疗并提高指南一致性。

研究设计与样本

  • 系统文献综述,检索PubMed和EMBASE数据库从建库至2023年7月,并手工筛选过去2年相关会议论文集。
  • 纳入回顾性或前瞻性观察性真实世界数据研究,评估mHSPC治疗模式。
  • 共检索到2336条引文,29项研究符合纳入标准,覆盖北美(美国n=21;加拿大n=2)、欧洲(n=8)和亚洲(n=6)。
  • 多数研究为回顾性队列(n=26),20项研究中位年龄≥70岁。

主要发现

  • ADT单药治疗在各地区均占主导,其次为ADT+ARPI和ADT+多西他赛,但亚洲各联合方案使用均较低。
  • 使用近期癌症中心/登记电子病历数据的研究显示,美国和欧洲ADT+ARPI使用超过40%。
  • 阿比特龙是最常用的ARPI,其次为恩扎卢胺。
  • 与ADT强化相关的定量因素包括高疾病负荷、较年轻年龄、ECOG体能状态评分0-1、较少合并症和肿瘤内科医生专科;定性因素包括患者偏好、对ADT反应不满意、耐受不良事件能力和无费用障碍。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To conduct a systematic literature review of real-world data (RWD) studies to summarise treatment patterns among men with metastatic hormone-sensitive prostate cancer (mHSPC). While androgen-deprivation therapy (ADT) is a primary treatment strategy for mHSPC, ADT intensification with androgen receptor pathway inhibitors (ARPIs) and/or chemotherapy is recommended by current guidelines and has improved clinical outcomes in the last decade. METHODS: We searched electronic databases (PubMed; Excerpta Medica dataBASE [EMBASE]) for eligible studies (retrospective or prospective observational RWD studies examining mHSPC treatment patterns) between database inception and July 2023, and manually screened the past 2 years of relevant conference proceedings. RESULTS: Of 2336 retrieved citations, 29 studies met the inclusion criteria, covering North America (United States, n = 21; Canada, n = 2), Europe (n = 8), and Asia (n = 6). Most studies utilised retrospective cohorts (n = 26) and included men with a median age of ≥70 years (n = 20). ADT monotherapy was predominantly used across geographies, followed by ADT + ARPI and ADT + docetaxel in the United States and Europe but not in Asia, where use of each combination remained low. Studies with recent electronic medical record data from cancer centres/registries showed >40% use of ADT + ARPI in the United States and Europe. Abiraterone was the most frequently used ARPI, followed by enzalutamide. Quantitative factors associated with ADT intensification were high disease burden, younger age, Eastern Cooperative Oncology Group performance status score of 0 to 1, fewer comorbidities, and oncologist physician specialty; qualitative factors were patient preference, unsatisfactory response to ADT, ability to tolerate adverse events, and absence of cost barriers. CONCLUSION: While there was an increasing trend in ADT intensification for mHSPC over the study period across geographies, use remained suboptimal considering the high proportion of patients who were still receiving ADT monotherapy only. These findings highlight the need for interventions to further optimise current mHSPC therapies with high guideline concordance.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Raval AD, Chen S, Littleton N, et al. Real-world use of androgen-deprivation therapy intensification for metastatic hormone-sensitive prostate cancer: a systematic review. BJU Int. 2024. PMID: 39530232. doi:10.1111/bju.16577

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。